Issue 1 | 16 February 2021
The TRACK trial will evaluate whether a small dose
of rivaroxaban, a blood-thinning medication, would reduce
cardiovascular death or major cardiovascular events in patients
with advanced stages of chronic kidney disease.
Meet the Investigators
Background and Rationale video available now;